HEINZ LENZ

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. ncbi request reprint Pharmacogenomics and colorectal cancer
    Heinz Josef Lenz
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 141 East Lake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Adv Exp Med Biol 587:211-31. 2006
  2. ncbi request reprint Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
  3. ncbi request reprint Targeting metastatic colorectal cancer in 2008: a long way from 5-FU
    Alexandra Pohl
    Division of Medical Oncology, Sharon A Carpenter Laboratory, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Oncology (Williston Park) 22:456-62; discussion 462-3, 467-8, 474 passim. 2008
  4. doi request reprint Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab
    Georg Lurje
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7884-95. 2008
  5. ncbi request reprint KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors
    Heinz Josef Lenz
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Clin Adv Hematol Oncol 6:1-13, 14-6. 2008
  6. pmc TAS-102, a novel antitumor agent: a review of the mechanism of action
    Heinz Josef Lenz
    USC Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, NOR 3456, Los Angeles, CA 90089 9173, United States Electronic address
    Cancer Treat Rev 41:777-83. 2015
  7. doi request reprint Panitumumab safety for treating colorectal cancer
    Stefan Stremitzer
    University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA 1 323 865 3967 1 323 865 0061
    Expert Opin Drug Saf 13:843-51. 2014
  8. pmc Cetuximab in the management of colorectal cancer
    Heinz Josef Lenz
    Division of Medical Oncology, University of Southern California Norris, Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
    Biologics 1:77-91. 2007
  9. pmc Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer
    O A Press
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics J 11:375-82. 2011
  10. pmc Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
    A Pohl
    Division of Medical Oncology, Sharon A Carpenter Laboratory, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics J 13:173-80. 2013

Collaborators

Detail Information

Publications70

  1. ncbi request reprint Pharmacogenomics and colorectal cancer
    Heinz Josef Lenz
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 141 East Lake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Adv Exp Med Biol 587:211-31. 2006
    ..Preliminary data suggest that germ line polymorphisms of cyclin D and gene expression levels of VEGF are associated with efficacy of Erbitux therapy...
  2. ncbi request reprint Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, California 95817, USA
    J Thorac Oncol 1:126-34. 2006
    ..This phase I study was performed to determine the dose-limiting toxicity and maximum tolerated dose (MTD) of docetaxel in combination with bortezomib in patients with advanced non-small cell lung cancer (NSCLC) or other solid tumors...
  3. ncbi request reprint Targeting metastatic colorectal cancer in 2008: a long way from 5-FU
    Alexandra Pohl
    Division of Medical Oncology, Sharon A Carpenter Laboratory, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Oncology (Williston Park) 22:456-62; discussion 462-3, 467-8, 474 passim. 2008
    ..This article reviews the mechanisms of action and possible markers of resistance, and summarizes data on the clinical efficacy of targeting agents...
  4. doi request reprint Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab
    Georg Lurje
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7884-95. 2008
    ..In this large molecular correlates study, we tested whether K-ras mutation status and polymorphisms in genes involved in the EGFR-signaling pathway were associated with clinical outcome in IMC-0144...
  5. ncbi request reprint KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors
    Heinz Josef Lenz
    Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Clin Adv Hematol Oncol 6:1-13, 14-6. 2008
    ..The following monograph includes discussions on the key issues surrounding the integration of recent data on KRAS status into the care of patients with this disease...
  6. pmc TAS-102, a novel antitumor agent: a review of the mechanism of action
    Heinz Josef Lenz
    USC Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, NOR 3456, Los Angeles, CA 90089 9173, United States Electronic address
    Cancer Treat Rev 41:777-83. 2015
    ..With its distinct mechanism of action and metabolism, TAS-102 is a promising treatment option for patients resistant to or intolerant of 5-FU-based fluoropyrimidines. ..
  7. doi request reprint Panitumumab safety for treating colorectal cancer
    Stefan Stremitzer
    University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA 1 323 865 3967 1 323 865 0061
    Expert Opin Drug Saf 13:843-51. 2014
    ..Recently, mutations in the RAS genes have been shown to be predictive of lack of efficacy, panitumumab should be restricted to patients with RAS wild-type (wt) tumors...
  8. pmc Cetuximab in the management of colorectal cancer
    Heinz Josef Lenz
    Division of Medical Oncology, University of Southern California Norris, Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
    Biologics 1:77-91. 2007
    ..Ongoing studies are exploring best combinations of cetuximab with these other agents to maximize patient outcome...
  9. pmc Gender-related survival differences associated with polymorphic variants of estrogen receptor-β (ERβ) in patients with metastatic colon cancer
    O A Press
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics J 11:375-82. 2011
    ..This study supports the role of an ERβ (CA)n repeat polymorphism as a prognostic marker in metastatic colon cancer; however, this prognostic factor had opposite implications based on gender...
  10. pmc Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy
    A Pohl
    Division of Medical Oncology, Sharon A Carpenter Laboratory, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Pharmacogenomics J 13:173-80. 2013
    ..5 months vs 9.8 months, P=0.004) in a multivariate analysis as an independent prognostic factor for PFS (adjusted P=0.002). These results suggest that CD133 is a predictive marker for standard first-line BV-based treatment in mCRC...
  11. pmc A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
    J Stoehlmacher
    Department of Hematology and Oncology, University of Hamburg, University Hospital, Hamburg 20247, Germany
    Br J Cancer 91:344-54. 2004
    ..These findings require independent prospective confirmation...
  12. doi request reprint Panitumumab : leading to better overall survival in metastatic colorectal cancer?
    Ana Sebio
    University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA 1 323 865 3967 1 323 865 0061
    Expert Opin Biol Ther 14:535-48. 2014
    ..Biomarkers within the EGFR pathway, such as K-Ras mutation, have proved to help better select the patients benefiting from these treatments...
  13. pmc Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy
    Yan Ning
    Corresponding Author Heinz Josef Lenz, Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, University of Southern California, Los Angeles, CA 90089
    Mol Cancer Ther 13:528-39. 2014
    ....
  14. doi request reprint Targeting IL-8 in colorectal cancer
    Yan Ning
    University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Division of Medical Oncology, Sharon A Carpenter Laboratory, 1441 Eastlake Ave, Suite3456, Los Angeles, CA 90089, USA 323 865 3955 1 323 865 0061
    Expert Opin Ther Targets 16:491-7. 2012
    ..Therefore, IL-8 and CXCR2 may be important therapeutic targets against colorectal cancer...
  15. doi request reprint Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!
    Sebastian Stintzing
    Keck School of Medicine, USC Norris Comprehensive Cancer Center, Sharon Carpenter Laboratory, 1441 Eastlake Avenue, Room 3456, Los Angeles, CA 90033, USA
    Expert Opin Pharmacother 14:2203-20. 2013
    ..Although showing promising activity in preclinical models, until now, the majority of KIs were not able to demonstrate clinically meaningful efficacy in Phase II/III trials...
  16. pmc Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States
    Takeru Wakatsuki
    Corresponding Author Heinz Josef Lenz, Sharon A Carpenter Laboratory, Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 1441 Eastlake Avenue, Los Angeles, CA 90033
    Mol Cancer Ther 12:2261-72. 2013
    ..These findings suggest that the estrogen pathway may play a prognostic role in patients with gastric cancer but this may be dependent on the regional differences both in physiology and genetic alterations of gastric cancer...
  17. pmc Influence of sex on the survival of patients with esophageal cancer
    Pierre Bohanes
    USC Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Ave, Room 3456, Los Angeles, CA 90033, USA
    J Clin Oncol 30:2265-72. 2012
    ....
  18. doi request reprint The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models
    Yan Ning
    Division of Medical Oncology, Sharon A Carpenter Laboratory, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Mol Cancer Ther 11:1353-64. 2012
    ..Taken together, these findings suggest that targeting CXCR2 may block tumor proliferation, migration, invasion, and angiogenesis. In addition, CXCR2 blockade may further sensitize colorectal cancer to oxaliplatin treatment...
  19. pmc DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines
    Melissa J LaBonte
    Department of Pathology Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    BMC Med Genomics 2:67. 2009
    ....
  20. ncbi request reprint Pharmacogenetic aspects in treatment of colorectal cancer--an update
    Jan Stoehlmacher
    GI Oncology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Pharmacogenomics 4:767-77. 2003
    ..Confirmed predictive markers, together with additional yet to be identified pharmacogenomic key players, will provide the basis for tailoring chemotherapy in the future...
  21. ncbi request reprint Management and preparedness for infusion and hypersensitivity reactions
    Heinz Josef Lenz
    University of Southern California, Los Angeles, USA
    Oncologist 12:601-9. 2007
    ..This article reviews the characteristics and management of hypersensitivity reactions to monoclonal antibodies and commonly used chemotherapy agents...
  22. ncbi request reprint Clinical update: proteasome inhibitors in solid tumors
    Heinz Josef Lenz
    USC Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Cancer Treat Rev 29:41-8. 2003
    ..Responses have been seen and no evidence of additive toxicity has been exhibited in combination agent trials...
  23. doi request reprint First-line combination treatment of colorectal cancer with hepatic metastases: choosing a targeted agent
    Heinz Josef Lenz
    Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Cancer Treat Rev 34:S3-7. 2008
    ..Genetic testing for specific mutations such as KRAS may be helpful for supporting a treatment decision to use cetuximab...
  24. ncbi request reprint Antiangiogenic agents in cancer therapy
    Heinz Josef Lenz
    USC Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, California 90033, USA
    Oncology (Williston Park) 19:17-25. 2005
    ..Future research will focus on determining the tumor types and stages that will benefit most from antiangiogenic therapy and combining therapies that target different factors in the angiogenesis pathway...
  25. ncbi request reprint Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study)
    Wu Zhang
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Anticancer Res 30:4209-17. 2010
    ..cetuximab and bevacizumab (CB)(BOND2)...
  26. ncbi request reprint Targeted therapy and pharmacogenomic programs
    Syma Iqbal
    Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Cancer 97:2076-82. 2003
    ..The next step is to develop clinical trials that will assess prospectively the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity...
  27. ncbi request reprint Gene polymorphisms of epidermal growth factor receptor and its downstream effector, interleukin-8, predict oxaliplatin efficacy in patients with advanced colorectal cancer
    Wu Zhang
    Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Colorectal Cancer 5:124-31. 2005
    ....
  28. ncbi request reprint Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: a Gynecologic Oncology Group study
    Agustin A Garcia
    Breast Cancer Program, Cedars Sinai Medical Center, Women s Cancer Research Institute, 8700 Beverly Boulevard Room 290 W, Los Angeles, CA 90048, USA
    Gynecol Oncol 96:810-7. 2005
    ....
  29. doi request reprint Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus
    Georg Lurje
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Ann Surg 251:857-64. 2010
    ..The aim of this study was to determine whether the risk of systemic disease after esophagectomy could be predicted by angiogenesis-related gene polymorphisms...
  30. doi request reprint A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy
    Peter M Wilson
    Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Chemother Pharmacol 65:979-88. 2010
    ..We conducted a phase I/II clinical trial to determine the safety and feasibility of combining vorinostat with 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer (mCRC) and elevated intratumoral thymidylate synthase (TS)...
  31. doi request reprint Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer
    Thomas Winder
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California, USA
    Gastroenterology 138:2163-76. 2010
    ..We review the most recent data on the VEGF and EGFR signaling pathways and therapeutic reagents designed to target them, provide insights into their mechanisms, and describe results from recent clinical trials...
  32. ncbi request reprint Exploring alternative individualized treatment strategies in colorectal cancer
    Peter M Wilson
    Department of Pathology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Colorectal Cancer 7:S28-36. 2007
    ..Together, these approaches are spearheading a paradigm shift toward individualized treatment strategies in CRC treatment...
  33. pmc Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab
    Anne M Schultheis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7554-63. 2008
    ..This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab...
  34. doi request reprint Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia
    Agustin A Garcia
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    J Clin Oncol 26:76-82. 2008
    ..A phase II trial was conducted to evaluate the antitumor activity and adverse effects of bevacizumab and metronomic oral cyclophosphamide in women with recurrent OC...
  35. ncbi request reprint Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer
    Wu Zhang
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 25:3726-31. 2007
    ..We tested the hypothesis of whether these two polymorphisms are associated with sex-specific clinical outcome in metastatic colon cancer patients treated with FU-based chemotherapy...
  36. ncbi request reprint Thymidylate synthase gene polymorphism predicts response to capecitabine in advanced colorectal cancer
    David J Park
    Department of Medical Oncology, Norris Cancer Center, University of Southern California, Los Angeles, USA
    Int J Colorectal Dis 17:46-9. 2002
    ..Our data suggest that genotyping patients for the thymidylate synthase polymorphism would be useful in identifying patients who are more likely to respond to capecitabine treatment for advanced colorectal cancer...
  37. ncbi request reprint Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
    Anthony B El-Khoueiry
    Division of Medical Oncology, Kenneth Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, 90033, USA
    Cancer Invest 24:50-5. 2006
    ..While clinical trials are ongoing to compare capecitabine to CI 5-FU, we believe that CI 5-FU should be offered to patients in the United States given its favorable toxicity profile and higher efficacy in several settings...
  38. ncbi request reprint Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab
    Wu Zhang
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Pharmacogenet Genomics 16:475-83. 2006
    ..004, log-rank test). The findings of this pilot study suggest that the cyclin D1 A870G and the EGF A61G polymorphisms may be useful molecular markers for predicting clinical outcome in CRC patients treated with single-agent Cetuximab...
  39. ncbi request reprint Capecitabine: the new generation of fluoropyrimidines in colorectal cancer
    Syma Iqbal
    University of Southern California, Kenneth Norris Comprehensive Cancer Center, Division of Medical Oncology, 1441 Eastlake Avenue, Suite 3457, Los Angeles, CA 90033, USA
    Expert Rev Anticancer Ther 4:947-55. 2004
    ..Ongoing clinical trials are evaluating the efficacy of capecitabine in combination with oxaliplatin and irinotecan as more convenient substitutes for infusional 5-FU in the 5-FU/leucovorin/oxaliplatin and 5-FU/irinotecan regimens...
  40. ncbi request reprint Molecular predictors of treatment and outcome in colorectal cancer
    Syma Iqbal
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3450, Los Angeles, CA 90033, USA
    Curr Gastroenterol Rep 5:399-405. 2003
    ..We discuss the ways in which determination of gene expression levels can enhance the treatment of colorectal cancer through prediction of patient response and tailoring of chemotherapy to the characteristics of an individual tumor...
  41. ncbi request reprint Tailored chemotherapy for colorectal cancer: a new approach to therapy
    Syma Iqbal
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, Los Angeles, California 90033, USA
    Cancer Invest 22:762-73. 2004
    ..The integration of these prognostic and predictive markers would allow individualized treatment for patients, maximizing therapeutic effect and minimizing exposure to toxicity...
  42. ncbi request reprint FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
    Wu Zhang
    Division of Medical Oncology, Department of Pathology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 25:3712-8. 2007
    ..We tested the hypothesis of whether these two polymorphisms are associated with clinical outcome in metastatic CRC patients treated with single-agent cetuximab...
  43. ncbi request reprint Pharmacogenomics in colorectal cancer
    Heinz Josef Lenz
    Division of Oncology, University of Southern California Norris Comprehensive Cancer Center, USC Keck School of Medicine, Los Angeles, CA 90033, USA
    Semin Oncol 30:47-53. 2003
    ..The next step is to develop clinical trials that will prospectively assess the benefits of profiling a patient's particular tumor, which should translate into an improvement in response and toxicity...
  44. doi request reprint Pharmacogenomics and -genetics in colorectal cancer
    Alexandra Pohl
    Division of Medical Oncology, University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Adv Drug Deliv Rev 61:375-80. 2009
    ..Individualized therapy will help to improve therapeutic efficacy and to minimize toxicities and therapeutic expenses...
  45. doi request reprint Molecular markers in the treatment of metastatic colorectal cancer
    Peter M Wilson
    Department of Pathology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
    Cancer J 16:262-72. 2010
    ..This review will highlight and discuss current progress in the search for biomarkers, the challenges this emerging field presents, and the future role of biomarkers in advancing CRC treatment...
  46. ncbi request reprint Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation
    Wu Zhang
    Division of Medical Oncology and Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA
    Clin Cancer Res 11:600-5. 2005
    ..05, log-rank test). Our data suggest that the HER-1 R497K and EGFR intron 1 (CA)(n) repeat polymorphisms may be potential indicators of radiosensitivity in patients with rectal cancer treated with chemoradiation...
  47. doi request reprint The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
    Melissa J LaBonte
    Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Int J Cancer 125:2957-69. 2009
    ..These results provide compelling preclinical rationale indicating lapatinib to be a potentially efficacious chemotherapeutic combination partner for irinotecan in the treatment of gastrointestinal carcinomas...
  48. ncbi request reprint Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer
    Agustin A Garcia
    University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, USA
    Int J Gastrointest Cancer 34:79-86. 2003
    ..Advanced pancreatic cancer has limited treatment options. 5-fluorouracil (5-FU) is frequently used in the treatment of pancreatic cancer. Preclinical studies suggest synergism between trimetrexate (TMTX),5-FU, and leucovorin (NFL)...
  49. doi request reprint Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer
    Georg Lurje
    Division of Medical Oncology, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA
    Pharmacogenet Genomics 19:95-102. 2009
    ....
  50. ncbi request reprint EGFR, HER2 and VEGF pathways: validated targets for cancer treatment
    Michael F Press
    Department of Pathology, Keck School of Medicine, Oncology, University of Southern California Norris Comprehensive Cancer Center, 14412 Eastlake Avenue, Los Angeles, CA 90033, USA
    Drugs 67:2045-75. 2007
    ..The results achieved with targeted therapies to date are promising, although they illustrate the need for additional preclinical and clinical study...
  51. doi request reprint Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
    William Fazzone
    Department of Pathology, Norris Comprehensive Cancer Center University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA
    Int J Cancer 125:463-73. 2009
    ..This study provides rationale for the continued clinical evaluation of HDACi in combination with 5-FU-based therapies as a strategy to overcome TS-mediated resistance...
  52. pmc Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage
    Peter M Wilson
    Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Nucleic Acids Res 37:78-95. 2009
    ..Furthermore, these studies provide the first evidence of a direct transcriptional link between the essential enzyme dUTPase and the tumor suppressor p53...
  53. doi request reprint Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer
    Oliver A Press
    Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Cancer Res 68:3037-42. 2008
    ..This study supports the role of functional EGFR polymorphisms as independent prognostic markers in metastatic colon cancer. As a prognostic factor, these variants had opposite prognostic implications based on gender...
  54. ncbi request reprint Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer
    Jan Stoehlmacher
    Department of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    J Natl Cancer Inst 94:936-42. 2002
    ....
  55. ncbi request reprint Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis
    Agustin A Garcia
    University of Southern California Keck School of Medicine, Kenneth Norris Jr Comprehensive Cancer Center, Los Angeles, CA, USA
    Invest New Drugs 24:79-83. 2006
    ..The objective of this phase I study was to determine the maximal tolerated dose (MTD) of the combination of weekly docetaxel and exisulind in patients with advanced solid tumors...
  56. ncbi request reprint Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients
    Mizutomo Azuma
    University of Southern California Norris Comprehensive Cancer Center, Division of Medical Oncology, The Sharon Carpenter Laboratory, Keck School of Medicine, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA 90033, USA
    Pharmacogenomics 8:1705-13. 2007
    ..e., VEGFA, VEGFR1-3, and neuropilin [NRP]1) are upregulated in metastatic colorectal cancer (mCRC) patients with high serum lactate dehydrogenase (LDH)...
  57. ncbi request reprint ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy
    David J Park
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles 90033, USA
    Clin Adv Hematol Oncol 1:162-6. 2003
    ..8-16.2) for those with C/T and T/T genotypes, respectively. The ERCC1 codon 118 polymorphism may be a useful predictor of clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy...
  58. ncbi request reprint Molecular prognostic markers in locally advanced colon cancer
    Georg Lurje
    Division of Medical Oncology, Sharon A Carpenter Laboratory, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Colorectal Cancer 6:683-90. 2007
    ..This review will discuss the most promising molecular prognostic markers and provide an update on the most recent developments...
  59. doi request reprint Molecular predictive and prognostic markers in colon cancer
    Thomas Winder
    Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Cancer Treat Rev 36:550-6. 2010
    ..This review aims to summarize the most important currently available predictive and prognostic molecular markers in colorectal cancer...
  60. ncbi request reprint ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan
    Katrin E Rhodes
    Divison of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Drug Metab Lett 1:23-30. 2007
    ..The combination of at least one SLCO1B1 521 T allele, one ABCB1 1236 C allele and one UGT1A1*28 variant 7 repeat demonstrated a statistically significant association with Grade 3/4 toxicities in metastatic colorectal cancer patients...
  61. doi request reprint Stem cells in colon cancer
    Alexandra Pohl
    Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA
    Clin Colorectal Cancer 7:92-8. 2008
    ..This review will provide an update of the biologic basis of the stem cell model and possible targets for the treatment of colon cancer...
  62. ncbi request reprint The -9Ala/-9Val polymorphism in the mitochondrial targeting sequence of the manganese superoxide dismutase gene (MnSOD) is associated with age among Hispanics with colorectal carcinoma
    Jan Stoehlmacher
    Department of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Oncol Rep 9:235-8. 2002
    ..Furthermore, the data suggest that the alanine allele of this polymorphism may be associated with an increased risk to develop colorectal cancer at a young age in Hispanics...
  63. pmc Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy
    Thomas Winder
    Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Oncologist 15:836-44. 2010
    ..The present review provides an update of the most recent data on the current therapy for pseudomyxoma peritonei (PMP) and mucinous colorectal adenocarcinoma (MCA) with metastatic disease confined to the peritoneum...
  64. pmc Gender disparities in metastatic colorectal cancer survival
    Andrew Hendifar
    Division of Medical Oncology and Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Clin Cancer Res 15:6391-7. 2009
    ..We investigated the interactions between sex, age, ethnicity, and year of diagnosis on overall survival (OS) in patients with metastatic colorectal cancer (MCRC)...
  65. doi request reprint Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer
    Georg Lurje
    Division of Medical Oncology, Department of Preventive Medicine, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA
    Pharmacogenet Genomics 18:161-8. 2008
    ....
  66. ncbi request reprint SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition
    Primo N Lara
    University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4772-81. 2003
    ..Efficacy was correlated with serial plasma VEGF and plasminogen activator inhibitor-1 levels and with positron emission tomography scans...
  67. ncbi request reprint Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a california cancer consortium phase I and molecular correlative study
    Primo N Lara
    California Cancer Consortium at the University of California Davis Cancer Center, Sacramento, California 95817, USA
    Clin Cancer Res 9:4356-62. 2003
    ..We conducted a Phase I study of tirapazamine, carboplatin, and paclitaxel and assessed potential plasma markers of hypoxia as surrogates for response...
  68. ncbi request reprint Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group
    James H Doroshow
    Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
    Semin Oncol 30:14-9. 2003
    ....
  69. ncbi request reprint Intermittent dosing of the farnesyl transferase inhibitor tipifarnib (R115777) in advanced malignant solid tumors: a phase I California Cancer Consortium Trial
    Primo N Lara
    University of California, Davis Cancer Center, Sacramento, CA 95817, USA
    Anticancer Drugs 16:317-21. 2005
    ..Three of these prolonged stable disease patients had non-small cell lung cancer. We conclude that intermittent dosing of R115777 is feasible and tolerable. The recommended phase II dose is 600 mg orally b.i.d. on alternate weeks...
  70. ncbi request reprint Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study
    Timothy W Synold
    City of Hope Comprehensive Cancer Center, Duarte, California, USA
    Clin Cancer Res 13:3660-6. 2007
    ..To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population...

Research Grants4

  1. Rectal Cancer: Molecular Markers of Outcome and Toxicity
    Heinz Josef Lenz; Fiscal Year: 2007
    ..Results from this study may aid in the development of future treatment strategies for patients with rectal cancer. ..
  2. DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS
    HEINZ LENZ; Fiscal Year: 2002
    ....
  3. DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY
    HEINZ LENZ; Fiscal Year: 2004
    ..This proposal will feature three beginning clinicians responsible for three different patient oriented projects taking advantage of our successful program in molecular outcome research. ..
  4. PHARMACOLOGY OF ANTICANCER DRUGS IN ADVANCED AGE
    HEINZ LENZ; Fiscal Year: 2003
    ....